FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Trial Profile

FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Fosbretabulin (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FOCUS
  • Sponsors Mateon Therapeutics
  • Most Recent Events

    • 16 Aug 2017 According to a Mateon Therapeutics media release, a total of 91 patients have been enrolled in the phase 2 portion of this study. The next (third) interim analysis will be conducted when approximatelyt 80 patient have been treated for at least two months or discontinued from the study, and it is anticipitated in Sep 2017.
    • 16 Aug 2017 Second interim results (n=40) published in a Mateon Therapeutics Media Release.
    • 01 Aug 2017 According to a Mateon Therapeutics media release, second interim analysis for 40 patients is anticipated in mid-August, the third for 60 patients in September, and the fourth and final interim analysis of all 80 plus patients in November 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top